Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

GLP-1 (glucagon-like peptide-1) discovered in the 1980s functions as a hormone derived from the proglucagon sequence and was found to have a transformative impact on the treatment of diabetes and ...

Kidney stones are among the possible risks of GLP-1 use that were not previously known. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) may have a wider range of benefits and risks than what ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY, rose 3% and 2.3% on Tuesday, respectively, after results from a study ...

You might be familiar with the top sellers, such as Eli ... as GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists. Novo Nordisk drugs are in the former category, while Lilly's are in ...